Abnormally expressed or malfunctioning proteins may affect or even damage cells, leading
to the onset of diseases. Proteolysis targeting chimera (PROTAC) technology has been …

Inducing protein degradation by proteolysis targeting chimera (PROTAC) has provided great
opportunities for scientific research and industrial applications. Histone deacetylase (HDAC) …

Estrogen receptor α (ERα) is a prime target for the treatment of ER-positive (ER+) breast
cancer. Despite the development of several effective therapies targeting ERα signaling …

The absence of effective active pockets makes traditional molecularly targeted drug
strategies ineffective against 80% of human disease-related proteins. The PROTAC …

MAF amplification increases the risk of breast cancer (BCa) metastasis through mechanisms
that are still poorly understood yet have important clinical implications. Oestrogen-receptor …

Proteolysis targeting chimera (PROTAC) technology has become a powerful strategy in drug
discovery, especially for undruggable targets/proteins. A typical PROTAC degrader consists …

Simple Summary The compounds named PROTACs are formed by two fragments, which
bring together a particular protein with a ubiquitinating enzyme. This allows ubiquitination …

Endocrine therapy (ET), also known as hormone therapy, refers to the treatment of tumors by
regulating and changing the endocrine environment and hormone levels. Its related …

Click chemistry is universally recognized as a powerful strategy for the fast and precise
assembly of diverse building blocks. Targeted Protein Degradation (TPD) is a new …

Annual breast cancer (BCa) deaths have declined since its apex in 1989 concomitant with
widespread adoption of hormone therapies that target estrogen receptor alpha (ERα), the …